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Choroidal metastasis as an initial presenting fea-ture of metastatic lung cancer is exceedingly rare.1 Furthermore, available literature about 
effective treatment strategies is limited. We present a 
clinical scenario involving a young male patient with 
bilateral choroidal metastases from lung cancer, and re-
view the relevant literature in an attempt to highlight 
the epidemiological features, pathological characters, 
therapeutic regimens and disease outcomes of this 
poorly understood disease entity.
CASE 
A 25-year-old man presented with decreased vision in 
the right eye for two weeks. He acknowledged smoking 
one pack of cigarettes daily for four years. Ophthalmic 
examination revealed his best corrected visual acuity 
to be 20/200 in the right eye and 20/20 in the left eye. 
Results of slit lamp examination were unremarkable. 
Funduscopic examination of the right eye showed an 
ill-defined, yellow-white elevated lesion in the choroid 
more than 10 times the disc diameter, involving the 
macula and the inferior edge of the fovea with associated 
serous retinal detachment (Figure 1A). Funduscopic ex-
amination of his left eye showed an ill-defined, yellow-
white elevated lesion in the choroid more than 5 times 
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Choroidal metastasis as an initial presenting feature of metastatic lung cancer is exceedingly rare. External 
beam radiotherapy (EBrt) is an effective and widely accepted therapeutic modality. however, data ad-
dressing the effectiveness of other treatment strategies is limited. We present a patient with choroidal 
metastases secondary to lung cancer and review the relevant literature. a 25-year-old male presented 
with deterioration of vision. his evaluation revealed bilateral choroidal metastasis secondary to adeno-
carcinoma of the lung. unfortunately, his vision continued to deteriorate despite treatment with EBrt and 
chemotherapy. Choroidal metastasis as an initial presentation of metastatic lung cancer is exceedingly 
rare, as only 30 cases have been reported. EBrt and systemic chemotherapy are effective therapeutic mo-
dalities. this case report could prove helpful to clinicians faced with a similar exceedingly rare scenario.
the disc diameter in size, nasal to the disc (Figure 1B). 
Fluorescein angiography of his right eye revealed early 
hypofluorescence and late phase showed hypofluores-
cence from the surface of his choroidal tumor associ-
ated with accumulated sub-retinal fluid. A B-scan ul-
trasound revealed a dome shaped, elevated choroidal 
lesion with moderate internal reflectivity. 
The remaining physical examination was normal ex-
cept for two hard subcutaneous nodules on his chest. In 
a search for a primary malignancy, imaging studies were 
done, which showed a left lung hilar mass, multiple liver 
metastasis, and widespread bone metastasis (Figure 2). 
A CT-guided lung biopsy as well as biopsy of the 
skin nodules was performed. The tumor showed pro-
liferation of groups of cells within a markedly des-
moplastic stroma (Figure 3A). The cells contained 
intra-cytoplasmic vacuoles that stained positive with 
mucicarmine stain (Figure 3B) consistent with adeno-
carcinoma. Immunohistochemistry positivity for TTF-
1 antibody was demonstrated (Figure 3C). Occasional 
tumor cells were positive for cytokeratin 5/6 and P63. 
The overall features were consistent with moderately 
differentiated adenocarcinoma of lung origin.
The patient was started on chemotherapy with 
cisplatin and docetaxel, and EBRT to both orbits. 
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Figure 1. a) right eye fundus examination showed a yellow-white elevated lesion in the chorois, inferiorly located involving the 
macula with associated serious retinal detachment. B) left eye funduscopy revealed a choroidal metastasis at the nasal edge of the 
optic disc.
Figure 2. a) Orbit Mri axial, T1 Wi’s post contrast image showing soft tissue nodular lesions in the posterior parts of the eye globes 
mainly at the right side, demonstrating homogeneous contrast enhancement. B) enhanced CT scan of teh cehst; mediastinal window 
shows left hilar soft tissue mass encasing the left main pulmonary artery. C) CT scan through the liver shows multiple hypodense liver 
lesions represent metastases. d) Bone scan demonstrates multiple active bone lesions represent metastases.
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Unfortunately, the patient continued to experience rap-
id deterioration of vision in the right eye (visual acuity 
dropped from 20/200 to counting fingers at 1 meter) 
and the left eye (visual acuity dropped from 20/20 to 
20/200). Funduscopic examination showed a right to-
tal serous retinal detachment (RD) and left nasal and 
inferior serous RD involving the macula. He received 
EBRT as 30 Gy/10 Fx over two weeks to both orbits 
via a pair of parallel-opposed beams. Following com-
pletion of radiotherapy, follow-up ophthalmic evalu-
ation (clinical and ultrasonic) showed stability in the 
size of choroidal lesions in both eyes but no regression 
of serous RD. Systemic steroids and posterior sub-
tenon steroid injections were applied as treatment for 
serous retinal detachment. Following the second cycle 
of chemotherapy, imaging studies revealed significant 
progression of lung mass and liver lesions. 
DISCUSSION
The choroid is a rare site of involvement by metastatic 
carcinomas. Godtfredsen2 reported only six patients 
(0.07%) in a survey that included 8712 patients with 
malignancy. Furthermore, choroidal involvement typi-
cally occurs late in the course of metastatic cancer.3 
Following breast neoplasm, lung cancer is the second 
most common cancer to metastasize to the choroid.1 
Postmortem examination of donated eyes of patients 
with carcinomas showed a 6.1% frequency of eye in-
volvement in patients dying of lung cancer; however, 
only 2.7% of all lung cancer patients in that series had 
gross metastasis while the remaining had only micro-
scopic metastasis.4 This finding suggests that most pa-
tients die when the choroidal metastasis is at a micro-
scopic stage and before developing visual symptoms, 
which explains the rarity of this site of metastasis as a 
presenting feature.
Characteristics of the 30 reported cases and their 
metastatic lung cancer are outlined in Table 1. At 25 
years, our patient is the youngest reported case of cho-
roidal metastases secondary to lung cancer. Nineteen 
patients (61 %) had accompanying retinal detach-
ment at their initial ophthalmologic evaluation. Most 
patients had multi-organ metastasis, with the brain, 
liver and bone as the most common metastatic sites. 
Choroidal metastasis can be distinguished from pri-
mary choroidal melanoma by clinical characteristics; 
typical choroidal metastasis is more often of a plateau-
shape than dome-shape; is yellow-white or mottled in 
color and associated with subretinal fluid and retinal 
detachment. FFA characterized by mottled hyper-
fluorescence in early stage while leakage in late stages 
and B-scan ultrasonography usually shows moderate 
reflectivity. Usually no biopsy is needed unless exten-
sive staging work up has failed to reveal the primary or 
other metastatic sites.5
EBRT is effective in treating and palliating patients 
with asymptomatic and symptomatic choroidal metas-
tases. Doses in the range of 3000 to 4000 cGy deliv-
ered via conventional fractionation are well tolerated 
and result in visual stabilization or improvement in 
up to 85% of cases.6-10 A unilateral radiation portal is 
appropriate in patients presenting with unilateral cho-
roidal metastasis.11 However, it should be noted that 
patients included in these studies had a diagnosis of 
Figure 3. Microscopic examination of the biopsy from lung mass. a) Sheets of tumor cells with acidophilic cytoplasm are seen 
(Hematoxylin and eosin, ×20). B) Mucicarmin stain highlighted intra-cytoplasmic mucin (×20). C) Positive nuclear staining with TTF-1 
(×20).
A B C
case reportCHOrOidal MeTaSTaSiS
Hematol Oncol Stem Cell Ther 5(1)     First Quarter 2012 hemoncstem.edmgr.com 63
Table 1. Characteristics of 30 reported cases with lung cancer and choroidal metastases.
Author/Journal Age (years)/ Gender Laterality Histology Metastatic sites Treatment
Choroidal response/
survival
Singh et al. J Med Case reports. 2010 
Jun 19;4:185. 50/M right adC not clear CTX Cr/not clear 
inoue et al.  eur J Ophthalmol. 2010 
Sep-Oct;20(5):963-5. 68/F Bilateral adC not clear gefitinib Pr/not clear
george et al.  J Thorac Oncol. 2009 
May;4(5):661-2. 42/F right lCC
Cervical ln, 
lung CTX and Bev Cr/aWd after 7 cycles
John et al.  J Thorac Oncol. 2010 
aug;5(8):1289. 56/M Bilateral SClC liver none not clear
lakhanpal et al.  ann Ophthalmol. 1982 
Sep;14(9):864-6. 38/F right adC Brain, bone eBrT and CTX
Pr after eBrT/dWd 
after 7 months
Cury Júnior et al.  arq Bras Oftalmol. 
2008 Mar-apr;71(2):291-4. 65/F left not clear Pleura not clear not clear
Kostrzewska et al.  Pol Merkur 
lekarski. 2011 Sep;31(183):171-4. 61/F Bilateral nSClC not clear CTX Cr/not clear
Herrag et al.  ann Thorac Surg. 2010 
Mar;89(3):1013-4; author reply 1014. 55/M right adC liver, bone CTX and eBrT Pr/not clear
Kaur et al.  am J Ophthalmol. 2007 
Feb;143(2):369-70. 51/F right adC no other sites
CTX and eBrT, 
enucleation
Pd/dWd after 7 
months
Mauget-Faÿsse et al.  acta Ophthalmol 
Scand. 2006 aug;84(4):552-4. 66/M right adC Bone, pleura CTX and PdT Pr/not clear
Shields et al.  retina. 2005 apr-
May;25(3):367-70 57/F left nSClC liver, pleura enucleation 
Pd/dWd after 11 
months
Shields et al.  Ophthalmic Surg lasers. 
2002 Jul-aug;33(4):323-5. 75/F left nSClC Brain CTX and WBrT
Cr/alive and FOP after 
>18 months
Matsuda et al.  nihon Kokyuki gakkai 
Zasshi. 2004 May;42(5):410-4. 51/F not clear adC not clear CTX and eBrT
not clear/dWd after 6 
months
Yamada et al.  nihon Kokyuki gakkai 
Zasshi. 2003 May;41(5):370-5. 69/M right adC no other sites not clear not clear
Hasturk et al.  lung Cancer. 2001 
apr;32(1):95-101. 51/M left lCC liver, bone CTX
not clear/dWd after 4 
months
leys.  retina. 2000;20(2):216-7. 62/M left SClC Bone CTX Pr/nd
egusa et al.  nihon Kyobu Shikkan 
gakkai Zasshi. 1996 Jan;34(1):121-5. 68/M left aSC no other sites enucleation
lt blindness/alive 
WOd at 7 months
Takano et al.  nihon Kyobu Shikkan 
gakkai Zasshi. 1995 Jun;33(6):674-7. 72/F Bilateral SCC Kidney CTX Pr/not clear
Marchini et al.  Stereotact Funct 
neurosurg. 1995;64 Suppl 1:67-71. 48/M left adC no other sites gamma knife 
Pr/alive and FOP after 
9 months
O’Connell et al.  Clin Oncol (r Coll 
radiol). 1990 May;2(3):177-9. 71/M right SCC no other sites
eBrT,  
enucleation
Pd/alive WOd at 4 
years
Simsek et al.  Med Oncol. 
2008;25(4):400-2. 45/M left nSClC
adrenal, porta-
hepatis ln CTX and eBrT
not clear/dWd at 6 
months
asteriou et al.  World J Surg Oncol. 
2010 Jan 8;8:2. 46/M left SCC
Bone, brain, 
adrenal CTX and  eBrT not clear
evans et al.  Thorax. 1971 Jul;26(4):472-
5.
45/M left nSClC Base of skull CTX Pr/dWd at 8 months
54/M right SCC liver, Brain enucleation only
not clear/dWd at 3 
months
53/F right nSClC not clear CTX Pr/dWd at 5 months
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Table 1 (cont.). Characteristics of 30 reported cases with lung cancer and choroidal metastases.
Author/Journal Age (years)/ Gender Laterality Histology Metastatic sites Treatment
Choroidal response/
survival
Tazi et al.  rev Med interne. 2006 
Sep;27(9):699-701. 28/M not clear adC Bone, liver, ln CTX Cr/not clear
Kreiger et al.  arch Ophthalmol. 1969 
aug;82(2):209-13. 57/M Bilateral not clear
liver, bone, 
kidney, adrenal, 
others
none not clear/dWd shortly after diagnosis
Battikh et al.  rev Pneumol Clin. 2004 
dec;60(6 Pt 1):353-6. 52/M not clear adC not clear CTX Cr/not clear
ascaso et al.  ann Thorac Surg. 2009 
Sep;88(3):1013-5. 42/F Bilateral adC
Bone, brain, 
meninges CTX not clear
Manor et al.  Br J Ophthalmol. 1978 
Feb;62(2):122-9. 44/M Bilateral SClC
liver, adrenal, 
kidney, brain, 
others
CTX and eBrT
Pd after CTX, Pr 
after eBrT/dWd at 5 
months
adC: adenocarcinoma; lCC: large cell carcinoma; SClC: small cell lung cancer; nSClC: non-small cell lung cancer; aSC: adenosquamous carcinoma; SCC: squamous cell carcinoma; ln: lymph nodes; CTX: 
chemotherapy; Bev: bevacizumab; eBrT: external beam radiotherapy; PdT: photodynamic therapy; WBrT: whole brain radiotherapy; Cr: complete response; Pr: partial response; aWd: alive with disease; Pd: 
progressive disease; dWd: died with disease; FOP: free of progression; WOd: without disease.
metastatic breast cancer and only a few presented with 
choroidal involvement secondary to a lung neoplasm.
The effectiveness of chemotherapy as a single mo-
dality in treating choroidal metastasis is not widely 
reported; however, a study in patients with breast can-
cer and choroidal metastasis concluded that systemic 
chemotherapy is as effective as radiotherapy as all six 
patients treated with systemic chemotherapy alone 
who showed regression of their choroidal metastasis.12 
Additionally, of the 30 reported cases we reviewed, 14 
patients were treated with chemotherapy without ad-
ditional EBRT; notably, 6 of the 14 patients had com-
plete resolution, and an additional 4 patients had par-
tial regression of the choroidal metastasis.
Although the available level of evidence supporting 
chemotherapy as a single modality in treating choroi-
dal metastasis is limited, it can be a reasonable alterna-
tive when EBRT is not readily available. Among our 
reviewed cases, all patients who received EBRT had 
also received chemotherapy, either concurrently or se-
quentially. Unfortunately, due to the paucity of data, 
it was difficult to derive firm conclusions about how 
these two modalities should best be integrated.
Choroidal metastasis is usually associated with 
widespread multi-organ metastases, and carries an ex-
tremely poor prognosis with survival counted in few 
months. In the extremely rare event when the choroid 
is the only metastatic site, enucleation of the affected 
eye may carry the advantages of confirming the patho-
logical diagnosis, palliating intractable pain and most 
importantly, offering a chance for long-term survival. 
O’Connell et al13 reported a patient who remained alive 
and free of recurrence 4 years following eye enucle-
ation.
Choroidal metastasis as an initial presentation of 
metastatic lung cancer is exceedingly rare. EBRT and 
systemic chemotherapy are effective treatment options 
associated with clinical and objective visual responses. 
This case report could prove helpful to clinicians faced 
with similar, however exceedingly rare scenario.
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